An NAD⁺ infusion and an NAD⁺ injection deliver the same molecule, and on the only figure that lets you compare them honestly — cost per milligram — the infusion costs roughly 13 to 21 times more.
That is not an estimate. It comes from two sellers’ own published numbers: The IV Doc charges $799 a session for a stated 250 mg, which is about $3.20 a milligram, against roughly $0.15–$0.25 a milligram for the injection sellers that publish a dose. Neither format has controlled outcome trials behind it.
What you are actually buying with the premium
Something real, and worth naming plainly: a clinician, a cannula, and in most cases somebody in the room for the hour or more the bag takes to run. Intravenous delivery also sidesteps every absorption question, which is the objection that hangs over anything swallowed.
What the premium is not buying is a better-evidenced result. There is no published trial comparing infused NAD⁺ with injected NAD⁺ on any clinical outcome, and there is no trial establishing either against placebo for the wellness indications both are sold for. That absence has been formally counted: a PRISMA-guided review published in early 2026 swept the NAD literature from January 2010 to October 2025, ended up with 113 eligible studies — 33 of them human intervention studies, 28 randomized — and found that not one eligible outcomes trial had evaluated intravenous or intramuscular NAD⁺ itself for an anti-aging or wellness indication [1].
The pharmacology nobody puts on the booking page
A pilot study followed the plasma and urine NAD⁺ metabolome during a six-hour intravenous infusion at 3 µmol per minute. Plasma NAD⁺ and its metabolites did not change until after two hours, and the authors concluded the infused NAD⁺ was being rapidly and completely removed from the plasma for at least those first two hours [2].
That finding is not an argument against infusions; it is an argument against the mental picture the marketing sells, in which a bag of NAD⁺ fills a depleted tank you can watch refill. Where the molecule goes and what it does after it leaves the plasma is not settled, for either route.
A critical review of intravenous longevity therapy published in early 2026 — covering high-dose vitamins, glutathione and NAD⁺ — reached a similar place from the clinical side: evidence comes largely from preclinical models and small clinical series, placebo-controlled trials are scarce and underpowered or conflicting, and until adequately powered randomized trials exist the practice should be regarded as experimental rather than evidence-based [3].
Comparing two prices that are not in the same units
This is where most buyers go wrong, and it is not their fault. An infusion is priced per session. An injection subscription is priced per month. Reading $799 against $149 as though they answer the same question is the single most common mistake in this category, and nothing on either checkout page warns you.
A course of infusions is rarely one session, and the number of sessions in a protocol is almost never published — so the annual cost of a drip program is usually unknowable from the seller’s own page. Our annual cost tool is built to expose exactly that gap, and the price comparison keeps the unit attached to each number so a session never quietly gets read as a month.
There is a second trap underneath the first: most sellers in both formats do not publish a milligram figure at all. Mobile IV Medics lists $749 an infusion and no dose, which means its price cannot be compared with The IV Doc’s $799 — or with anything else. A price without a quantity is not a price you can shop on.
Side effects differ, and the difference is about rate
People receiving NAD⁺ drips commonly report flushing, chest tightness, nausea and cramping during the infusion, which clinics manage by slowing the drip. Those are practice reports rather than trial findings, and they are a property of pushing a large amount of the molecule in quickly. A subcutaneous injection delivers a smaller quantity more slowly and is generally described differently by the people taking it.
Neither observation is a safety clearance. What is actually known about NAD⁺ side effects is format-dependent, and the honest summary for both of these routes is that it has not been characterized in controlled trials. Both are compounded preparations, which means they are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed.
How to choose
If you want the drip for the experience — the supervision, the hour, the clinician in the room — book it knowing what the per-milligram figure is, and knowing that the premium buys delivery rather than demonstrated results.
If what you want is the molecule at the lowest defensible price, the injection route is where the published doses and the cheaper milligrams are, and the cheapest NAD⁺ therapy board ranks on exactly that. If you want the format with actual randomized human trials behind its biomarker claim, that is neither of these — it is an oral precursor, at a fraction of the cost of both.